Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Health Canada has not approved BPC-157 as a health product or prescription drug
Selected Data 1) The study conducted by researchers Tukhovskaya et al aimed to investigate the neuroprotective and motor function recovery effects of intranasal Delta Sleep-Inducing Peptide (DSIP) in Sprague-Dawley (SD) rats subjected to focal stroke induced by middle cerebral artery occlusion (MCAO)
DSIPs effects on the CRF pathway and cortisol regulation make it particularly relevant for stress-induced sleep problems
Products sold online "for research use only" are not approved, manufactured, or quality-controlled for human use, and buying them carries quality and legal risk
BPC-157 was classified as a Category 2 bulk drug substance in 2023, meaning it cannot be compounded by commercial pharmacies
While specific data on micronutrient status during tirzepatide therapy are limited, clinical experience suggests that maintaining optimal nutritional status supports the preservation of lean muscle mass during weight loss, enhances energy levels, and promotes overall treatment tolerability and success
US$ 23.74
US$ 21.89
US$ 21.58
US$ 29.48
US$ 24.54
